Connable Office Inc. Trims Holdings in Becton Dickinson and Co (BDX)
Connable Office Inc. trimmed its position in shares of Becton Dickinson and Co (NYSE:BDX) by 4.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 14,556 shares of the medical instruments supplier’s stock after selling 648 shares during the quarter. Connable Office Inc.’s holdings in Becton Dickinson and were worth $3,116,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Becton Dickinson and by 8.5% in the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after buying an additional 1,353,780 shares in the last quarter. State Street Corp raised its position in shares of Becton Dickinson and by 3.5% in the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after buying an additional 342,873 shares in the last quarter. Northern Trust Corp raised its position in shares of Becton Dickinson and by 4.0% in the second quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after buying an additional 106,966 shares in the last quarter. Fundsmith LLP raised its position in shares of Becton Dickinson and by 0.3% in the second quarter. Fundsmith LLP now owns 2,302,590 shares of the medical instruments supplier’s stock worth $449,258,000 after buying an additional 5,977 shares in the last quarter. Finally, Mawer Investment Management Ltd. raised its position in shares of Becton Dickinson and by 1.4% in the third quarter. Mawer Investment Management Ltd. now owns 1,799,828 shares of the medical instruments supplier’s stock worth $352,599,000 after buying an additional 24,761 shares in the last quarter. 75.56% of the stock is owned by institutional investors and hedge funds.
BDX has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Wells Fargo & Co reiterated a “positive” rating and issued a $235.00 price objective (up previously from $225.00) on shares of Becton Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Royal Bank of Canada reiterated a “hold” rating and issued a $210.00 price objective on shares of Becton Dickinson and in a research report on Wednesday, October 25th. Morgan Stanley increased their price objective on Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 price objective on shares of Becton Dickinson and in a research report on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $237.27.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter last year, the business posted $2.33 earnings per share. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. equities research analysts forecast that Becton Dickinson and Co will post 10.95 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be given a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a yield of 1.37%. Becton Dickinson and’s payout ratio is 229.01%.
In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the sale, the director now owns 295,753 shares in the company, valued at $64,420,918.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.00% of the company’s stock.
WARNING: “Connable Office Inc. Trims Holdings in Becton Dickinson and Co (BDX)” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://theolympiareport.com/2018/02/13/connable-office-inc-trims-holdings-in-becton-dickinson-and-co-bdx.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.